Mitomycin C (MMC) is widely used in the treatment of various solid tumours, including human bladder carcinoma (Crooke & Bradner, 1976; Carter, 1979) . However, the frequent occurrence of resistance to MMC limits its clinical effectiveness (Moertel et al., 1968; Lenaz, 1985) . Elucidation of the biochemical mechanism(s) leading to MMC resistance may, therefore, be essential for developing strategies to increase the therapeutic value of this drug.
MMC requires enzymatic bioactivation, and metabolic pathways for one-and two-electron reduction of MMC leading to the generation of cytotoxic species have been described (Iyer & Szybalski, 1963; Pan et al., 1984; Tomasz et al., 1987; Siegel et al., 1992) . While many enzymes have been implicated in MMC bioactivation, NADPH cytochrome P450 reductase and DT diaphorase appear to be the key enzymes involved in its bioreductive activation (Keyes et al., 1984; Pan et al., 1984; Hoban et al., 1990; Gustafson & Pritsos, 1992; Siegel et al., 1992) . Whereas the most abundant lesion produced by enzymatically activated MMC is the DNA monoadduct, MMC is believed to exert cytotoxic activity primarily through the formation of DNA-DNA cross-links (Long et al., 1984; Dorr et al., 1985; Tomasz et al., 1987) . MMC-dependent oxyradicals have also been proposed to contribute to its cytotoxicity (Pan et al., 1984; Dusre et al., 1990) .
Several independent investigators have shown that cellular resistance to MMC often results from deficient drug activation due to the down-regulation of bioactivation enzymes (Willson et al., 1985 (Willson et al., , 1987 Marshall et al., 1989; Hoban et al., 1990; Pan et al., 1992) . On the other hand, MMC resistance in a subclone of the L1210 leukaemic cell line appears to be due to reduced drug accumulation (Dorr et al., 1987) . Cross-resistance to MMC in a multidrug-resistant clone of the MCF-7 human breast cancer cell line (ADR), selected for resistance to doxorubicin, has been attributed to the reduced formation of MMC-dependent oxyradicals (Dusre et al., 1990) .
Recent studies suggest that GSH/GST-mediated drug inactivation may also play an important role in MMC resistance (Perry et al., 1992; Siegel et al., 1992; Singh et al., 1992; Xu & Singh, 1992a) . We have shown that cross-resistance to MMC in a multidrug-resistant variant of P388 mouse leukaemia (P388/R-84) is independent of either deficient drug activation or reduced drug accumulation, but seems to be influenced by GSH/GST levels (Singh et al., 1992; Xu & Singh, 1992a,b) . Subsequently, using a panel of three unrelated human bladder cancer cell lines (J82, HT-1 197 and SCaBER) differing in their sensitivities to MMC, we noticed a good correlation between MMC cytotoxicity and GST level, activity being highest in the relatively insensitive cell line (SCaBER) and lowest in the comparatively sensitive cell line, J82 (Xu et al., 1993 (Xu & Singh, 1992a, b Enzyme assays NADPH cytochrome P450 reductase activity was determined by the procedure described by Hrycay et al. (1975) . DT diaphorase was measured according to the method described by Ernster (1967) using 2,6-dichlorophenol indophenol (DCPIP) as a substrate. The concentration of dicoumarol used to study the inhibition of the reduction of DCPIP was 10 iM. GSH peroxidase and catalase activities were determined by the methods described by Beutler (1984) . Protein content was determined by the method of Bradford (1976) .
MMC-dependent lipid peroxidation MMC-dependent oxyradical formation in J82 and SCaBER cell lines was compared by monitoring the production of 2-thiobarbituric acid-reactive malondialdehyde (an indicator of oxyradical formation). Malondialdehyde content was determined according to the method described by Konings & Drijver (1979) with slight modifications. The details of the lipid peroxidation assay have been described by us previously (Xu & Singh, 1992b) .
Alkaline elution assay Cells (0.5 x 106 in 5 ml of complete medium) were labelled with [14C]thymidine (0.02 ItCi ml-'; specific activity, 56 mCi mmol-') for 48 h. The medium was removed and the cells were washed twice with PBS. The radioactivity was chased by a 24 h post-incubation at 37°C in fresh medium containing 10 ZlM non-radioactive thymidine. The labelled cells were incubated with different concentrations of MMC for 1 h at 37°C, and washed twice with ice-cold PBS. Aliquots containing approximately 1 x 106 cells were irradiated with 15 Gy of y-radiation on ice. DNA cross-link formation was determined by using the alkaline elution technique as described by Kohn et al. (1981) . Interstrand cross-link (ISC) frequency was calculated by using the equation:
where Ro and RI represent the fraction of DNA retained from control and MMC-treated cells respectively.
Results
The in vitro cytotoxicity of MMC, BMY 25282 and BMY 25067 in J82 and SCaBER cell lines is shown in Figure 1 .
The IC50 value for MMC in SCaBER cells (1.5 ± 0.15 ILM)
was 5-fold higher (P<0.001) than in J82 (0.3 ± 0.04 pM) (Figure la) . BMY 25282 and BMY 25067 appeared to be significantly more cytotoxic, on a molar basis, than the parent drug in both these cell lines (Figure lb and c) (Table II) . We have shown previously that the GSH level is also similar in J82 and SCaBER cell lines (Xu et al., 1993) .
Since cross-linking of DNA is believed to be important in the cytotoxic activity of MMC (Long et 2). MMC-induced ISC frequencies, at three drug concentrations, were markedly lower in the SCaBER cell line than in J82. The ISC frequencies induced by 0.75, 3.75 and 7.50 JAM MMC in the SCaBER cell line were about 44%, 15% and 58%, respectively of those in J82 cells.
Discussion
Whereas several different mechanisms have been proposed to account for MMC resistance (Dorr et al., 1987; Willson et al., 1987; Marshall et al., 1989; Dusre et al., 1990; Singh et al., 1992) have much lower quinone reduction potential than the parent drug (Doyle & Vyas, 1990) . Thus, BMY 25282 has exhibited superior anti-tumour activity in certain MMC-resistant cells (for review see Doyle & Vyas, 1990) . In the present study also BMY 25282 appeared to be more active than MMC in both the cell lines. These results suggest that BMY 25282 may be a superior anti-tumour agent to MMC. Unfortunately, the toxicity of BMY 25282 has limited its clinical use (Doyle & Vyas, 1990) . While the reduction potentials of BMY 25067 and MMC are similar, this analogue has displayed much lower haematological toxicity such as neutropenia than MMC in preclinical studies (Bradner et al., 1990) . Interestingly, both the bladder cell lines examined in this study were significantly more sensitive to BMY 25067 than MMC. Relatively higher cytotoxicity of BMY 25067 compared with MMC has also been reported in other cell lines (Dusre et al., 1990; Xu & Singh, 1992a) . Similarly, BMY 25067 exhibited superior activity against B16 melanoma with a high percentage of cures in mice when both the tumours and drugs were given i.p. or in B16 melanoma implanted s.c. and BMY 25067 administered i.v. (Bradner et al., 1990) . These results suggest that BMY 25067 may be seriously considered for further clinical development because of its superior cytotoxicity and lower toxicity than the parent compound.
The cytotoxicity of MMC is suggested to be mediated by DNA-DNA cross-linking and oxygen radical-mediated damage (Dorr et al., 1985; Dusre et al., 1990) . Although a good correlation has been reported between MMC cytotoxicity and DNA cross-link formation (Long et al., 1984; Dorr et al., 1985) , the contribution of oxyradicals in the activity of this agent is not as clear. Dusre et al. (1990) have suggested that relatively lower sensitivity of the MCF-7.ADR cell line to MMC, BMY 25282 and BMY 25067 compared with wild-type MCF-7 cells results from the reduced oxygen radical formation. Previous studies from our laboratory (Xu & Singh, 1992b) have also shown reduced MMC-dependent oxyradical formation in P388/R-84 cells, which are significantly cross-resistant to MMC, compared with P388/S cells. suggested that, although oxygen radicals do contribute to the aerobic cytotoxicity of MMC and BMY 25282, the cytotoxic lesions occur at site(s) other than DNA. However, McGurl and Kennedy (1989) have concluded that oxyradicals may not play a role in the anti-tumour activity of this drug. In this study, sensitivity to MMC did not seem to correlate with oxyradical formation. In fact, MMC-dependent lipid peroxidation was significantly higher in MMC-resistant SCaBER cells. Although the present study does not provide evidence either for or against a role of oxyradicals in MMC cytotoxicity, this mechanism does not appear to contribute to the differential sensitivity of J82 and SCaBER cells to MMC.
In the present study, the activities of two key MMC bioactivation enzymes, NADPH cytochrome P450 reductase and DT diaphorase, were significantly lower in SCaBER cells than in J82 cells. These results suggest that the relatively lower sensitivity of the SCaBER cell line to MMC and perhaps BMY 25067 may be due to the deficient drug activation. The observation that the ICm values for BMY 25282 in J82 and SCaBER cell lines did not differ significantly provides further support for this premise.
MMC has been shown to be preferentially cytotoxic to hypoxic tumour cells (Kennedy et al., 1980; Rockwell, 1983 ).
U-'
Several MMC-resistant cell lines, with deficient drug activation as mechanism of MMC resistance, have exhibited parental sensitivity to this agent under hypoxic conditions (Dulhanty et al., 1989; Marshall et al., 1989; Hoban et al., 1990 ).
Although the experiments described in the present study were performed under aerobic conditions, it remains to be seen if the sensitivity of the SCaBER cell line to MMC is similar to that of J82 under hypoxic conditions. The results of the present study suggest that, in addition to the deficient bioactivation, reduced DNA cross-linking may also contribute to the relatively lower sensitivity of SCaBER cells to MMC. However, further studies are needed to determine whether reduced DNA cross-linking in the SCaBER cell line is a consequence of deficient drug activation or results from the increased repair of the damaged DNA in these cells.
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